Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving.We analysed time to progression, overall survival, and the mutational status of RAS, BRAF...